Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Searching for ways to earn money with little time? Discover effective strategies to make money even with a packed schedule.
23,073 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
A sizable stake in Pampa Energia signals renewed interest in Argentina's energy complex. This article breaks down wha...
Opendoor stock popped today amid optimism about profitability progress and better unit economics. This article breaks...
A Life360 board director recently sold several thousand shares after exercising options, timing that coincides with a...
This article breaks down Quaker Chemical's Q4 2025 earnings implications, real-world drivers, and practical steps you...
Marc Zeller’s audit of Aave Labs has sparked new tensions in the AaveDAO as supporters and critics spar over a $51 mi...
This piece examines which stocks people actually search for and why those trends matter. Learn how to separate curios...
A jailed crypto founder weighs in on a high-stakes regulatory bill, and senators from both parties push back. The cla...
We unpack the Q4 results and what ftai (fip) 2025 earnings imply for the year ahead. Learn the key drivers, risk fact...
Nike is back in focus as consumer demand shows resilience and the market digests the athletic giant's performance. Th...
Palantir trades near the $150 level amid volatility. This guide breaks down whether palantir technologies stock no-br...
Traders seek faster funding, clearer terms and better payouts in 2026. This report analyzes the best prop trading fir...